Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

作者：Wei Zhou, Adrian Lim, Mouad Edderkaoui, Arsen Osipov, Heshui Wu, Qiang Wang, Stephen Jacob Pandol · 发表于：International Journal of Biological Sciences · 年份：2023 · DOI：10.7150/ijbs.83586 · 被引用次数：41 · 研究领域：Hippo pathway signaling and YAP/TAZ

Although recent advances in cancer treatment significantly improved the prognosis of patients, drug resistance remains a major challenge. Targeting programmed cell death is a major approach of antitumor drug development. Deregulation of programmed cell death (PCD) contributes to resistance to a variety of cancer therapeutics. Yes-associated protein (YAP) and its paralog TAZ, the main downstream effectors of the Hippo pathway, are aberrantly activated in a variety of human malignancies. The Hippo-YAP pathway, which was originally identified in Drosophila, is well conserved in humans and plays a defining role in regulation of cell fate, tissue growth and regeneration. Activation of YAP signaling has emerged as a key mechanism involved in promoting cancer cell proliferation, metastasis, and drug resistance. Understanding the role of YAP/TAZ signaling network in PCD and drug resistance could facilitate the development of effective strategies for cancer therapeutics.